NCT00620113View on ClinicalTrials.gov

Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

PHASE2CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

December 3, 2007

Primary Completion Date

May 29, 2009

Study Completion Date

May 29, 2009

Conditions
Osteoporosis Postmenopausal
Interventions
DRUG

Odanacatib

Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.

DIETARY_SUPPLEMENT

Vitamin D3

Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.

DIETARY_SUPPLEMENT

Calcium carbonate

Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.

DRUG

Placebo

Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00620113 - Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) | Biotech Hunter | Biotech Hunter